Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities

{ 'indexed': {'date-parts': [[2024, 8, 11]], 'date-time': '2024-08-11T00:28:19Z', 'timestamp': 1723336099552}, 'publisher-location': 'Berlin, Heidelberg', 'reference-count': 117, 'publisher': 'Springer Berlin Heidelberg', 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024]]}, 'DOI': '10.1007/82_2024_268', 'type': 'book-chapter', 'created': {'date-parts': [[2024, 8, 10]], 'date-time': '2024-08-10T13:04:12Z', 'timestamp': 1723295052000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities', 'prefix': '10.1007', 'author': [{'given': 'Daniele', 'family': 'Focosi', 'sequence': 'first', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 8, 11]]}, 'reference': [ { 'key': '268_CR1', 'doi-asserted-by': 'publisher', 'unstructured': 'ACTIV-3/TICO LY-CoV555 Study Group (2020) A neutralizing monoclonal ' 'antibody for hospitalized patients with Covid-19. N Engl J Med ' '384(10):905–914. https://doi.org/10.1056/NEJMoa2033130', 'DOI': '10.1056/NEJMoa2033130'}, { 'key': '268_CR2', 'unstructured': 'ACTIV-3: Therapeutics for Inpatients With COVID-19—Full Text ' 'View—ClinicalTrials.gov'}, { 'key': '268_CR3', 'doi-asserted-by': 'publisher', 'unstructured': 'Anderson TS, O’Donoghue A, Mechanic O, Dechen T, Stevens J (2022) ' 'Administration of anti–SARS-CoV-2 monoclonal antibodies after US food ' 'and drug administration deauthorization. JAMA Netw Open 5(8):e2228997-e. ' 'https://doi.org/10.1001/jamanetworkopen.2022.28997', 'DOI': '10.1001/jamanetworkopen.2022.28997'}, { 'key': '268_CR4', 'unstructured': 'AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE ' 'Phase III outpatient treatment trial (2022). Accessed online at ' 'https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html ' 'on 22 Feb 2022'}, { 'issue': 'S0085–2538', 'key': '268_CR5', 'doi-asserted-by': 'publisher', 'first-page': '00383', 'DOI': '10.1016/j.kint.2022.05.008', 'volume': '22', 'author': 'I Benotmane', 'year': '2022', 'unstructured': 'Benotmane I, Velay A, Thaunat O, Vargas GG, Olagne J, Fafi-Kremer S et ' 'al (2022) Pre-exposure prophylaxis with Evusheld™ elicits limited ' 'neutralizing activity against the Omicron variant in kidney transplant ' 'patients. Kidney Int 22(S0085–2538):00383. ' 'https://doi.org/10.1016/j.kint.2022.05.008', 'journal-title': 'Kidney Int'}, { 'issue': '7838', 'key': '268_CR6', 'doi-asserted-by': 'publisher', 'first-page': '485', 'DOI': '10.1038/s41586-020-2838-z', 'volume': '588', 'author': 'S Bournazos', 'year': '2020', 'unstructured': 'Bournazos S, Corti D, Virgin HW, Ravetch JV (2020) Fc-optimized ' 'antibodies elicit CD8 immunity to viral respiratory infection. Nature ' '588(7838):485–490. https://doi.org/10.1038/s41586-020-2838-z', 'journal-title': 'Nature'}, { 'key': '268_CR7', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-021-04386-2', 'author': 'E Cameroni', 'year': '2021', 'unstructured': 'Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K et al ' '(2021) Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron ' 'antigenic shift. Nature. https://doi.org/10.1038/s41586-021-04386-2', 'journal-title': 'Nature'}, { 'key': '268_CR8', 'doi-asserted-by': 'publisher', 'unstructured': 'Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A et al (2022) Imprinted ' 'SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. ' 'Nature. https://doi.org/10.1038/s41586-022-05644-7', 'DOI': '10.1038/s41586-022-05644-7'}, { 'key': '268_CR9', 'doi-asserted-by': 'crossref', 'unstructured': 'Casadevall A, Focosi D (2023) SARS-CoV-2 variants resistant to ' 'monoclonal antibodies in immunocompromised patients is a public health ' 'concern. J Clin Invest', 'DOI': '10.1172/JCI168603'}, { 'key': '268_CR10', 'doi-asserted-by': 'publisher', 'unstructured': 'Dalakas MC, Spaeth PJ (2021) The importance of FcRn in ' 'neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, ' 'IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol ' 'Disord. https://doi.org/10.1177/1756286421997381', 'DOI': '10.1177/1756286421997381'}, { 'issue': '9', 'key': '268_CR11', 'doi-asserted-by': 'publisher', 'first-page': '886', 'DOI': '10.1097/inf.0000000000001916', 'volume': '37', 'author': 'JB Domachowske', 'year': '2018', 'unstructured': 'Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T et al ' '(2018) Safety, tolerability and pharmacokinetics of MEDI8897, an ' 'extended half-life single-dose respiratory syncytial virus prefusion ' 'F-targeting monoclonal antibody administered as a single dose to healthy ' 'preterm infants. Pediatr Infect Dis J 37(9):886–892. ' 'https://doi.org/10.1097/inf.0000000000001916', 'journal-title': 'Pediatr Infect Dis J'}, { 'key': '268_CR12', 'doi-asserted-by': 'crossref', 'unstructured': 'Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A et al ' '(2024) Real-world effectiveness of sotrovimab for the treatment of ' 'SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a ' 'systematic literature review. Infection 52:1–17', 'DOI': '10.1007/s15010-023-02098-5'}, { 'key': '268_CR13', 'unstructured': 'ETF statement on the loss of activity of anti-spike protein monoclonal ' 'antibodies due to emerging SARS-CoV-2 variants of concern (2022). 9 ' 'December 2022 EMA/931457/2022. Accessed online at ' 'https://www.ema.europa.eu/en/documents/public-statement/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2_en.pdf'}, { 'key': '268_CR14', 'unstructured': 'ETF warns that monoclonal antibodies may not be effective against ' 'emerging strains of SARS-CoV-2 (2023). Accessed online at ' 'https://www.ema.europa.eu/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2 ' 'on 24 Jan 2023'}, { 'issue': '5', 'key': '268_CR15', 'doi-asserted-by': 'publisher', 'first-page': '658', 'DOI': '10.7326/m22-3428', 'volume': '176', 'author': 'TH Evering', 'year': '2023', 'unstructured': 'Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA et al ' '(2023) Safety and efficacy of combination SARS-CoV-2 neutralizing ' 'monoclonal antibodies Amubarvimab plus Romlusevimab in nonhospitalized ' 'patients With COVID-19. Ann Intern Med 176(5):658–666. ' 'https://doi.org/10.7326/m22-3428', 'journal-title': 'Ann Intern Med'}, { 'key': '268_CR16', 'unstructured': 'Fact sheet for healthcare providers: emergency use authorization for ' 'bebtelovimab (2022). Accessed online at ' 'https://www.fda.gov/media/156152/download on 21 Feb 2022'}, { 'key': '268_CR17', 'unstructured': 'FDA (2022) Coronavirus (COVID-19) update: FDA authorizes New monoclonal ' 'antibody for treatment of COVID-19 that retains activity against Omicron ' 'variant. Accessed online at ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains ' 'on 17 Feb 2022'}, { 'key': '268_CR18', 'unstructured': 'FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region ' '(2022). Accessed online at ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region ' 'on 1 Dec 2022'}, { 'key': '268_CR19', 'unstructured': 'FDA announces Evusheld is not currently authorized for emergency use in ' 'the U.S. (2023) Accessed online at ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us ' 'on 3 Feb 2023'}, { 'key': '268_CR20', 'unstructured': 'FDA Statement (2022) Coronavirus (COVID-19) update: FDA limits use of ' 'certain monoclonal antibodies to treat COVID-19 due to the Omicron ' 'variant. ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron ' 'Accessed 8 June 2023'}, { 'key': '268_CR21', 'unstructured': 'FDA updates Sotrovimab emergency use authorization. March 30, 2022. ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization ' 'Accessed 9 June 2023'}, { 'key': '268_CR22', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/rmv.2231', 'author': 'D Focosi', 'year': '2021', 'unstructured': 'Focosi D, Maggi F (2021) Neutralising antibody escape of SARS-CoV-2 ' 'spike protein: risk assessment for antibody-based Covid-19 therapeutics ' 'and vaccines. Rev Med Virol. https://doi.org/10.1002/rmv.2231', 'journal-title': 'Rev Med Virol'}, { 'key': '268_CR23', 'doi-asserted-by': 'publisher', 'first-page': '219', 'DOI': '10.2217/fmb-2021-0286', 'volume': '17', 'author': 'D Focosi', 'year': '2022', 'unstructured': 'Focosi D, Maggi F, McConnell S, Casadevall A (2022a) Spike mutations in ' 'SARS-CoV-2 AY sublineages of delta variant of concern: implications for ' 'the future of the pandemic. Future Microbiol 17:219–221. ' 'https://doi.org/10.2217/fmb-2021-0286', 'journal-title': 'Future Microbiol'}, { 'issue': '1', 'key': '268_CR24', 'doi-asserted-by': 'crossref', 'first-page': '29', 'DOI': '10.3390/ijms23010029', 'volume': '23', 'author': 'D Focosi', 'year': '2022', 'unstructured': 'Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A (2022b) ' 'Analysis of immune escape variants from antibody-based therapeutics ' 'against COVID-19: a systematic review. Int J Mol Sci 23(1):29', 'journal-title': 'Int J Mol Sci'}, { 'issue': '11', 'key': '268_CR25', 'doi-asserted-by': 'publisher', 'first-page': '00311', 'DOI': '10.1016/S1473-3099(22)00311-5', 'volume': '22', 'author': 'D Focosi', 'year': '2022', 'unstructured': 'Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M ' '(2022c) Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect ' 'Dis 22(11):00311–00315. https://doi.org/10.1016/S1473-3099(22)00311-5', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '3', 'key': '268_CR26', 'doi-asserted-by': 'crossref', 'first-page': '2264', 'DOI': '10.3390/ijms24032264', 'volume': '24', 'author': 'D Focosi', 'year': '2023', 'unstructured': 'Focosi D, Quiroga R, McConnell S, Johnson MC, Casadevall A (2023a) ' 'Convergent evolution in SARS-CoV-2 Spike creates a variant soup from ' 'which new COVID-19 waves emerge. Int J Mol Sci 24(3):2264', 'journal-title': 'Int J Mol Sci'}, { 'key': '268_CR27', 'doi-asserted-by': 'crossref', 'unstructured': 'Focosi D (2023) A web tool to estimate baaseline anti-Spike monoclonal ' 'antibody efficacy based on regional genomic surveillance. Viruses ' '15(5):1048', 'DOI': '10.3390/v15051048'}, { 'key': '268_CR28', 'doi-asserted-by': 'crossref', 'unstructured': 'Focosi D, Maggi F (2023) Respiratory delivery of passive immunotherapies ' 'for SARS-CoV-2 prophylaxis and therapy. Hum Vaccines Immunotherap 19(2)', 'DOI': '10.1080/21645515.2023.2260040'}, { 'key': '268_CR29', 'doi-asserted-by': 'publisher', 'unstructured': 'Focosi D, Tuccori M (2022) Prescription of anti-spike monoclonal ' 'antibodies in COVID-19 patients with resistant SARS-CoV-2 variants in ' 'Italy. Pathogens (Basel, Switzerland) 11(8). ' 'https://doi.org/10.3390/pathogens11080823', 'DOI': '10.3390/pathogens11080823'}, { 'key': '268_CR30', 'doi-asserted-by': 'publisher', 'unstructured': 'Focosi D, McConnell S, Sullivan DJ, Casadevall A (2023b) Analysis of ' 'SARS-CoV-2 mutations associated with resistance to therapeutic ' 'monoclonal antibodies that emerge after treatment. Drug Resist Updates ' '100991. https://doi.org/10.1016/j.drup.2023.100991', 'DOI': '10.1016/j.drup.2023.100991'}, { 'key': '268_CR31', 'unstructured': 'Francica J, Rosenthal K, Ren K, Flores DJ et al (2023) The SARS-CoV-2 ' 'monoclonal antibody AZD3152 potently neutralises historical and ' 'currently circulating variants. ECCMID. Copenhagen'}, { 'key': '268_CR32', 'doi-asserted-by': 'publisher', 'unstructured': 'Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J et al (2021) ' 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial. JAMA 325(7):632–644. ' 'https://doi.org/10.1001/jama.2021.0202%JJAMA', 'DOI': '10.1001/jama.2021.0202%JJAMA'}, { 'key': '268_CR42', 'doi-asserted-by': 'crossref', 'unstructured': 'Group RC, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G et al ' '(2022) Casirivimab and imdevimab in patients admitted to hospital with ' 'COVID-19 (RECOVERY): a randomised, controlled, open-label, platform ' 'trial. Lancet 399(10325):665–676. ' 'https://doi.org/10.1016/S0140-6736(22)00163-5', 'DOI': '10.1016/S0140-6736(22)00163-5'}, { 'key': '268_CR33', 'doi-asserted-by': 'publisher', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR et ' 'al (2021) Early treatment for Covid-19 with SARS-CoV-2 neutralizing ' 'antibody sotrovimab. N Engl J Med 385:1941–1950. ' 'https://doi.org/10.1056/NEJMoa2107934', 'DOI': '10.1056/NEJMoa2107934'}, { 'issue': '10', 'key': '268_CR34', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1009542', 'volume': '17', 'author': 'K Haga', 'year': '2021', 'unstructured': 'Haga K, Takai-Todaka R, Matsumura Y, Song C, Takano T, Tojo T et al ' '(2021) Nasal delivery of single-domain antibody improves symptoms of ' 'SARS-CoV-2 infection in an animal model. PLoS Pathog 17(10):e1009542. ' 'https://doi.org/10.1371/journal.ppat.1009542', 'journal-title': 'PLoS Pathog'}, { 'key': '268_CR35', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ve/veac104', 'author': 'PJ Halfmann', 'year': '2022', 'unstructured': 'Halfmann PJ, Minor NR, Haddock LA III, Maddox R, Moreno GK, Braun KM et ' 'al (2022) Evolution of a globally unique SARS-CoV-2 Spike E484T ' 'monoclonal antibody escape mutation in a persistently infected, ' 'immunocompromised individual. Virus Evol. ' 'https://doi.org/10.1093/ve/veac104', 'journal-title': 'Virus Evol'}, { 'issue': '6428', 'key': '268_CR36', 'doi-asserted-by': 'publisher', 'first-page': '446', 'DOI': '10.1038/363446a0', 'volume': '363', 'author': 'C Hamers-Casterman', 'year': '1993', 'unstructured': 'Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, ' 'Songa EB et al (1993) Naturally occurring antibodies devoid of light ' 'chains. Nature 363(6428):446–448. https://doi.org/10.1038/363446a0', 'journal-title': 'Nature'}, { 'key': '268_CR37', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.virs.2023.07.003', 'author': 'Q Han', 'year': '2023', 'unstructured': 'Han Q, Wang S, Wang Z, Zhang C, Wang X, Feng N et al (2023) Nanobodies ' 'with cross-neutralizing activity provide prominent therapeutic efficacy ' 'in mild and severe COVID-19 rodent models. Virologica Sinica. ' 'https://doi.org/10.1016/j.virs.2023.07.003', 'journal-title': 'Virologica Sinica'}, { 'issue': '2', 'key': '268_CR38', 'doi-asserted-by': 'crossref', 'first-page': '530', 'DOI': '10.3390/v15020530', 'volume': '15', 'author': 'L Hao', 'year': '2023', 'unstructured': 'Hao L, Hsiang T-Y, Dalmat RR, Ireton R, Morton JF, Stokes C et al (2023) ' 'Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal ' 'protection against Omicron. Viruses 15(2):530', 'journal-title': 'Viruses'}, { 'key': '268_CR39', 'doi-asserted-by': 'crossref', 'unstructured': 'Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J et al ' '(2022) Comparison of the risk of hospitalisation among BA.1 and BA.2 ' 'COVID-19 cases treated with Sotrovimab in the community in England. ' 'Influenza Other Respi Viruses 17(5):e13150. ' 'https://doi.org/10.1111/irv.13150', 'DOI': '10.1111/irv.13150'}, { 'issue': '2', 'key': '268_CR40', 'doi-asserted-by': 'publisher', 'first-page': '250', 'DOI': '10.1067/mai.2001.116576', 'volume': '108', 'author': 'TK Hart', 'year': '2001', 'unstructured': 'Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE ' 'et al (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), ' 'a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J ' 'Allergy Clin Immunol 108(2):250–257. ' 'https://doi.org/10.1067/mai.2001.116576', 'journal-title': 'J Allergy Clin Immunol'}, { 'key': '268_CR41', 'doi-asserted-by': 'publisher', 'unstructured': 'He Q, Wu L, Xu Z, Wang X, Xie Y, Chai Y et al (2023) An updated atlas of ' 'antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and ' 'XBB. Cell Rep Med 4(4):100991. ' 'https://doi.org/10.1016/j.xcrm.2023.100991', 'DOI': '10.1016/j.xcrm.2023.100991'}, { 'key': '268_CR43', 'doi-asserted-by': 'crossref', 'unstructured': 'Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan Y-H et al ' '(2021) Structural definition of a pan-sarbecovirus neutralizing epitope ' 'on the spike S2 subunit. Commun Biol. ' 'https://doi.org/10.1038/s42003-022-03262-7', 'DOI': '10.1101/2021.08.02.454829'}, { 'key': '268_CR44', 'unstructured': 'IDSA Guidelines on the Treatment and Management of Patients with ' 'COVID-19 (2022). Accessed online at ' 'https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ ' 'on 9 Feb 2022'}, { 'issue': '7906', 'key': '268_CR45', 'doi-asserted-by': 'publisher', 'first-page': '553', 'DOI': '10.1038/s41586-022-04594-4', 'volume': '604', 'author': 'S Iketani', 'year': '2022', 'unstructured': 'Iketani S, Liu L, Guo Y, Liu L, Huang Y, Wang M et al (2022) Antibody ' 'evasion properties of SARS-CoV-2 Omicron sublineages. Nature ' '604(7906):553–556. https://doi.org/10.1038/s41586-022-04594-4', 'journal-title': 'Nature'}, { 'key': '268_CR46', 'doi-asserted-by': 'publisher', 'unstructured': 'Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S et al (2022) ' 'Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. ' 'N Engl J Med. https://doi.org/10.1056/NEJMc2214302', 'DOI': '10.1056/NEJMc2214302'}, { 'key': '268_CR47', 'doi-asserted-by': 'crossref', 'unstructured': 'Isa F, Forleo-Neto E, Meyer J, Zheng W, Rasmussen S, Armas D et al ' '(2021) Repeat subcutaneous administration of REGEN-COV® in adults is ' 'well-tolerated and prevents the occurrence of COVID-19. Int J Infect ' 'Dis. https://doi.org/10.1016/j.ijid.2022.06.045', 'DOI': '10.1016/j.ijid.2022.06.045'}, { 'key': '268_CR48', 'doi-asserted-by': 'publisher', 'unstructured': 'Ison MG, Weinstein DF, Dobryanska M, Holmes A, Phelan A-M, Li Y et al ' '(2023) Prevention of COVID-19 following a single intramuscular ' 'administration of Adintrevimab: results from a phase 2/3 randomized, ' 'double-blind, placebo-controlled trial (EVADE). Open Forum Infect Dis ' '10(7). https://doi.org/10.1093/ofid/ofad314', 'DOI': '10.1093/ofid/ofad314'}, { 'key': '268_CR49', 'doi-asserted-by': 'publisher', 'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, ' 'Delos Reyes V et al (2022) Molnupiravir for oral treatment of Covid-19 ' 'in nonhospitalized patients. N Engl J Med 386(6):509–520. ' 'https://doi.org/10.1056/NEJMoa2116044', 'DOI': '10.1056/NEJMoa2116044'}, { 'key': '268_CR50', 'doi-asserted-by': 'crossref', 'unstructured': 'Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Alfredo Amolong ' 'Hinay J et al (2023) Virological characteristics of the SARS-CoV-2 JN.1 ' 'variant. Lancet Infect Dis. ' 'https://doi.org/10.1016/S1473-3099(23)00813-7', 'DOI': '10.1101/2023.12.08.570782'}, { 'key': '268_CR51', 'doi-asserted-by': 'publisher', 'unstructured': 'Kaplon H, Chenoweth A, Crescioli S, Reichert JM (2022) Antibodies to ' 'watch in 2022. mAbs 14(1):2014296. ' 'https://doi.org/10.1080/19420862.2021.2014296', 'DOI': '10.1080/19420862.2021.2014296'}, { 'key': '268_CR52', 'doi-asserted-by': 'publisher', 'unstructured': 'Ku Z, Xie X, Lin J, Gao P, Sahili AE, Su H et al (2022) Engineering ' 'SARS-CoV-2 cocktail antibodies into a bispecific format improves ' 'neutralizing potency and breadth. medRxiv. ' 'https://doi.org/10.1101/2022.02.01.478504', 'DOI': '10.1101/2022.02.01.478504'}, { 'key': '268_CR53', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116620', 'author': 'MJ Levin', 'year': '2022', 'unstructured': 'Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A et al ' '(2022) Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of ' 'Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2116620', 'journal-title': 'N Engl J Med'}, { 'key': '268_CR54', 'doi-asserted-by': 'crossref', 'unstructured': 'Li C, Zhan W, Yang Z, Tu C, Zhu Y, Song W et al (2021) Broad ' 'neutralization of SARS-CoV-2 variants by an inhalable bispecific ' 'single-domain antibody. Cell. https://doi.org/10.1016/j.cell.2022.03.009', 'DOI': '10.1101/2021.12.30.474535'}, { 'issue': '3', 'key': '268_CR55', 'doi-asserted-by': 'publisher', 'first-page': 'e336', 'DOI': '10.1093/cid/ciac448', 'volume': '76', 'author': 'Y Lin', 'year': '2023', 'unstructured': 'Lin Y, Yue S, Yang Y, Yang S, Pan Z, Yang X et al (2023) Nasal spray of ' 'neutralizing monoclonal antibody 35B5 confers potential prophylaxis ' 'against severe acute respiratory syndrome coronavirus 2 variants of ' 'concern: a small-scale clinical trial. Clin Infect Dis 76(3):e336–e341. ' 'https://doi.org/10.1093/cid/ciac448', 'journal-title': 'Clin Infect Dis'}, { 'key': '268_CR56', 'doi-asserted-by': 'crossref', 'unstructured': 'Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D et al (2021) Robust induction ' 'of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 ' 'vaccine. Cell Discov. https://doi.org/10.1038/s41421-022-00373-7', 'DOI': '10.1101/2021.09.12.21263373'}, { 'key': '268_CR57', 'doi-asserted-by': 'publisher', 'first-page': '35', 'DOI': '10.1016/j.prrv.2018.12.001', 'volume': '33', 'author': 'MS Luna', 'year': '2020', 'unstructured': 'Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A et al (2020) ' 'Expert consensus on palivizumab use for respiratory syncytial virus in ' 'developed countries. Paediatr Respir Rev 33:35–44. ' 'https://doi.org/10.1016/j.prrv.2018.12.001', 'journal-title': 'Paediatr Respir Rev'}, { 'issue': '10', 'key': '268_CR58', 'doi-asserted-by': 'publisher', 'first-page': '905', 'DOI': '10.1056/NEJMoa2033130', 'volume': '384', 'author': 'JD Lundgren', 'year': '2021', 'unstructured': 'Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky ' 'U et al (2021) A neutralizing monoclonal antibody for hospitalized ' 'patients with Covid-19. N Engl J Med 384(10):905–914. ' 'https://doi.org/10.1056/NEJMoa2033130', 'journal-title': 'N Engl J Med'}, { 'key': '268_CR59', 'doi-asserted-by': 'publisher', 'unstructured': 'Martinez DR, Schäfer A, Gobeil S, Li D, De la Cruz G, Parks R et al ' '(2022) A broadly cross-reactive antibody neutralizes and protects ' 'against sarbecovirus challenge in mice. Sci Transl Med 14(629):eabj7125. ' 'https://doi.org/10.1126/scitranslmed.abj7125', 'DOI': '10.1126/scitranslmed.abj7125'}, { 'key': '268_CR60', 'doi-asserted-by': 'crossref', 'unstructured': 'McSweeney MD, Stewart I, Richardson Z, Kang H, Park Y, Kim C et al ' '(2022) Stable nebulization and muco-trapping properties of ' 'Regdanvimab/IN-006 support its development as a potent, dose-saving ' 'inhaled therapy for COVID-19. Bioeng Transl Med. ' 'http://doi.org/10.1002/btm2.10391', 'DOI': '10.1101/2022.02.27.482162'}, { 'issue': '9', 'key': '268_CR61', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1009958', 'volume': '17', 'author': 'N Mishra', 'year': '2021', 'unstructured': 'Mishra N, Kumar S, Singh S, Bansal T, Jain N, Saluja S et al (2021) ' 'Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly ' 'neutralizing antibodies and polyclonal plasma. PLoS Pathog ' '17(9):e1009958. https://doi.org/10.1371/journal.ppat.1009958', 'journal-title': 'PLoS Pathog'}, { 'issue': '4', 'key': '268_CR62', 'doi-asserted-by': 'publisher', 'first-page': '230', 'DOI': '10.1016/s0968-0004(01)01790-x', 'volume': '26', 'author': 'S Muyldermans', 'year': '2001', 'unstructured': 'Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by ' 'single-domain antibody fragments: the superfluous luxury of paired ' 'domains. Trends Biochem Sci 26(4):230–235. ' 'https://doi.org/10.1016/s0968-0004(01)01790-x', 'journal-title': 'Trends Biochem Sci'}, { 'key': '268_CR63', 'doi-asserted-by': 'publisher', 'unstructured': 'Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB ' 'et al (2021) Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 ' 'infections in Syrian hamsters at ultra-low doses. Sci Adv 7(22). ' 'https://doi.org/10.1126/sciadv.abh0319', 'DOI': '10.1126/sciadv.abh0319'}, { 'issue': '2', 'key': '268_CR64', 'doi-asserted-by': 'publisher', 'first-page': '164', 'DOI': '10.1006/clim.2000.4975', 'volume': '98', 'author': 'R Newman', 'year': '2001', 'unstructured': 'Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D et ' 'al (2001) Modification of the Fc region of a primatized IgG antibody to ' 'human CD4 retains its ability to modulate CD4 receptors but does not ' 'deplete CD4+ T cells in chimpanzees. Clin Immunol 98(2):164–174. ' 'https://doi.org/10.1006/clim.2000.4975', 'journal-title': 'Clin Immunol'}, { 'key': '268_CR65', 'doi-asserted-by': 'publisher', 'first-page': '1184', 'DOI': '10.1056/NEJMoa2109682', 'volume': '385', 'author': 'MP O’Brien', 'year': '2021', 'unstructured': 'O’Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan K-C, Sarkar N et al ' '(2021) Subcutaneous REGEN-COV antibody combination to prevent Covid-19. ' 'N Engl J Med 385:1184–1195. https://doi.org/10.1056/NEJMoa2109682', 'journal-title': 'N Engl J Med'}, { 'key': '268_CR66', 'doi-asserted-by': 'publisher', 'unstructured': 'Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K et al (2022) ' 'Different efficacies of neutralizing antibodies and antiviral drugs on ' 'SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. Antiviral Res. ' 'https://doi.org/10.1016/j.antiviral.2022.105372', 'DOI': '10.1016/j.antiviral.2022.105372'}, { 'issue': '6579', 'key': '268_CR67', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.1126/science.abm8143', 'volume': '375', 'author': 'YJ Park', 'year': '2022', 'unstructured': 'Park YJ, De Marco A, Starr TN, Liu Z, Pinto D, Walls AC et al (2022) ' 'Antibody-mediated broad sarbecovirus neutralization through ACE2 ' 'molecular mimicry. Science 375(6579):449–454. ' 'https://doi.org/10.1126/science.abm8143', 'journal-title': 'Science'}, { 'key': '268_CR68', 'doi-asserted-by': 'publisher', 'unstructured': 'Patel V, Levick B, Boult S, Gibbons DC, Drysdale M, Lloyd EJ et al ' '(2023) Characteristics and outcomes of COVID-19 patients presumed to be ' 'treated with sotrovimab in NHS hospitals in England. medRxiv. ' 'https://doi.org/10.1101/2023.02.08.23285654', 'DOI': '10.1101/2023.02.08.23285654'}, { 'issue': '1', 'key': '268_CR69', 'doi-asserted-by': 'publisher', 'first-page': '77', 'DOI': '10.1016/0022-1759(94)00275-2', 'volume': '179', 'author': 'RS Peebles Jr', 'year': '1995', 'unstructured': 'Peebles RS Jr, Liu MC, Lichtenstein LM, Hamilton RG (1995) IgA, IgG and ' 'IgM quantification in bronchoalveolar lavage fluids from allergic ' 'rhinitics, allergic asthmatics, and normal subjects by monoclonal ' 'antibody-based immunoenzymetric assays. J Immunol Methods 179(1):77–86. ' 'https://doi.org/10.1016/0022-1759(94)00275-2', 'journal-title': 'J Immunol Methods'}, { 'key': '268_CR70', 'doi-asserted-by': 'publisher', 'unstructured': 'Piepenbrink MS, Park J-G, Deshpande A, Loos A, Ye C, Basu M et al (2022) ' 'Potent universal-coronavirus therapeutic activity mediated by direct ' 'respiratory administration of a Spike S2 domain-specific human ' 'neutralizing monoclonal antibody. bioRxiv. ' 'https://doi.org/10.1101/2022.03.05.483133', 'DOI': '10.1101/2022.03.05.483133'}, { 'issue': '6559', 'key': '268_CR71', 'doi-asserted-by': 'publisher', 'first-page': '1109', 'DOI': '10.1126/science.abj3321', 'volume': '373', 'author': 'D Pinto', 'year': '2021', 'unstructured': 'Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP et ' 'al (2021) Broad betacoronavirus neutralization by a stem helix-specific ' 'human antibody. Science 373(6559):1109–1116. ' 'https://doi.org/10.1126/science.abj3321', 'journal-title': 'Science'}, { 'key': '268_CR72', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.annonc.2021.07.015', 'author': 'F Pommeret', 'year': '2021', 'unstructured': 'Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A et al ' '(2021) Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape ' 'mutations and secondary clinical deterioration in COVID-19 patients with ' 'B-cell malignancies. Ann Oncol. ' 'https://doi.org/10.1016/j.annonc.2021.07.015', 'journal-title': 'Ann Oncol'}, { 'key': '268_CR73', 'doi-asserted-by': 'crossref', 'unstructured': 'Qu P, Xu K, Faraone JN, Goodarzi N, Zheng Y-M, Carlin C et al (2023) ' 'Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 Omicron ' 'BA.2.86 and FLip variants. Cell. ' 'https://doi.org/10.1016/j.cell.2023.12.026', 'DOI': '10.1101/2023.09.11.557206'}, { 'key': '268_CR74', 'doi-asserted-by': 'publisher', 'unstructured': 'Qu P, Faraone JN, Evans JP, Zheng YM, Carlin C, Anghelina M et al (2023) ' 'Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, ' 'CH.1.1, and CA.3.1 variants. Cell Rep 42(5):112443. ' 'https://doi.org/10.1016/j.celrep.2023.112443', 'DOI': '10.1016/j.celrep.2023.112443'}, { 'issue': '11', 'key': '268_CR75', 'doi-asserted-by': 'publisher', 'first-page': '815', 'DOI': '10.1016/j.tips.2020.07.004', 'volume': '41', 'author': 'A Renn', 'year': '2020', 'unstructured': 'Renn A, Fu Y, Hu X, Hall MD, Simeonov A (2020) Fruitful neutralizing ' 'antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci ' '41(11):815–829. https://doi.org/10.1016/j.tips.2020.07.004', 'journal-title': 'Trends Pharmacol Sci'}, { 'key': '268_CR76', 'unstructured': 'Reuters (2022) GSK-Vir therapy has neutralising activity against Omicron ' 'sub-variant, data shows. Accessed online at ' 'https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-vir-therapy-works-against-omicron-sub-variant-data-suggests-2022-02-10/ ' 'on 15 Feb 2022'}, { 'issue': '12', 'key': '268_CR77', 'doi-asserted-by': 'publisher', 'first-page': '6147', 'DOI': '10.1128/aac.01285-13', 'volume': '57', 'author': 'GJ Robbie', 'year': '2013', 'unstructured': 'Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA et ' 'al (2013) A novel investigational Fc-modified humanized monoclonal ' 'antibody, motavizumab-YTE, has an extended half-life in healthy adults. ' 'Antimicrob Agents Chemother 57(12):6147–6153. ' 'https://doi.org/10.1128/aac.01285-13', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '268_CR78', 'doi-asserted-by': 'publisher', 'unstructured': 'Sabin AP, Richmond CS, Kenny PA (2022) Emergence and onward transmission ' 'of a SARS-CoV-2 E484K variant among household contacts of a ' 'bamlanivimab-treated patient. Diagn Microbiol Infect Dis 103(1):115656. ' 'https://doi.org/10.1101/2021.10.02.21264415%JmedRxiv', 'DOI': '10.1101/2021.10.02.21264415%JmedRxiv'}, { 'key': '268_CR79', 'doi-asserted-by': 'publisher', 'unstructured': 'Sanderson T, Hisner R, Donovan-Banfield I, Peacock T, Ruis C (2023) A ' 'molnupiravir-associated mutational signature in global SARS-CoV-2 ' 'genomes. Nature. https://doi.org/10.1038/s41586-023-06649-6', 'DOI': '10.1038/s41586-023-06649-6'}, { 'key': '268_CR80', 'doi-asserted-by': 'publisher', 'unstructured': 'Saunders KO (2019) Conceptual approaches to modulating antibody effector ' 'functions and circulation half-life. Front Immunol 10. ' 'https://doi.org/10.3389/fimmu.2019.01296', 'DOI': '10.3389/fimmu.2019.01296'}, { 'key': '268_CR81', 'doi-asserted-by': 'publisher', 'unstructured': 'Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S et ' 'al (2020) Antibody potency, effector function, and combinations in ' 'protection and therapy for SARS-CoV-2 infection in vivoIn vivo efficacy ' 'of anti–SARS-CoV-2 antibodies. J Exp Med 218(3). ' 'https://doi.org/10.1084/jem.20201993', 'DOI': '10.1084/jem.20201993'}, { 'issue': '10', 'key': '268_CR82', 'doi-asserted-by': 'publisher', 'first-page': '457', 'DOI': '10.1093/protein/gzw040', 'volume': '29', 'author': 'T Schlothauer', 'year': '2016', 'unstructured': 'Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick ' 'C et al (2016) Novel human IgG1 and IgG4 Fc-engineered antibodies with ' 'completely abolished immune effector functions. Protein Eng Des Select ' 'PEDS 29(10):457–466. https://doi.org/10.1093/protein/gzw040', 'journal-title': 'Protein Eng Des Select PEDS'}, { 'issue': '5', 'key': '268_CR83', 'doi-asserted-by': 'publisher', 'first-page': '622', 'DOI': '10.1016/S1473-3099(21)00751-9', 'volume': '22', 'author': 'WH Self', 'year': '2022', 'unstructured': 'Self WH, Sandkovsky U, Reilly CS, Vock DM, Gottlieb RL, Mack M et al ' '(2022) Efficacy and safety of two neutralising monoclonal antibody ' 'therapies, sotrovimab and BRII-196 plus BRII-198, for adults ' 'hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet ' 'Infect Dis 22(5):622–635. https://doi.org/10.1016/S1473-3099(21)00751-9', 'journal-title': 'Lancet Infect Dis'}, { 'key': '268_CR84', 'doi-asserted-by': 'publisher', 'unstructured': 'Sheward DJ, Yang Y, Westerberg M, Öling S, Muschiol S, Sato K et al ' '(2023) Sensitivity of BA.2.86 to prevailing neutralising antibody ' 'responses. Lancet Infect Dis. https://doi.org/10.1101/2023.09.02.556033', 'DOI': '10.1101/2023.09.02.556033'}, { 'key': '268_CR85', 'doi-asserted-by': 'publisher', 'unstructured': 'Shrestha LB, Tedla N, Bull RA (2021) Broadly-neutralizing antibodies ' 'against emerging SARS-CoV-2 variants. Front Immunol 12:752003. ' 'https://doi.org/10.3389/fimmu.2021.752003', 'DOI': '10.3389/fimmu.2021.752003'}, { 'key': '268_CR86', 'unstructured': 'Some States Still Pushing Ineffective Covid Antibody Treatments (2022). ' 'Accessed online at https://www.medscape.com/viewarticle/967020. Accessed ' 'on 26 April 2022'}, { 'key': '268_CR87', 'doi-asserted-by': 'publisher', 'unstructured': 'Song R, Zeng G, Yu J, Meng X, Chen X, Li J et al (2023) Post-exposure ' 'prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray ' 'for the prevention of symptomatic COVID-19 in healthy adult workers: a ' 'randomized, single-blind, placebo-controlled clinical study. Emerg ' 'Microbes Infect 2212806. https://doi.org/10.1080/22221751.2023.2212806', 'DOI': '10.1080/22221751.2023.2212806'}, { 'key': '268_CR88', 'doi-asserted-by': 'crossref', 'unstructured': 'Stadler E, Chai KL, Schlub TE, Cromer D, Polizzotto MN, Kent SJ et al ' '(2022a) Determinants of passive antibody efficacy in SARS-CoV-2 ' 'infection. Lancet Microbe. https://doi.org/10.1016/S2666-5247(23)00194-5', 'DOI': '10.1101/2022.03.21.22272672'}, { 'key': '268_CR89', 'doi-asserted-by': 'crossref', 'unstructured': 'Stadler E, Burgess MT, Schlub TE, Chai KL, McQuilten ZK, Wood EM et al ' '(2022b) Monoclonal antibody levels and protection from COVID-19. Nat ' 'Commun. https://doi.org/10.1038/s41467-023-40204-1', 'DOI': '10.1101/2022.11.22.22282199'}, { 'issue': '1', 'key': '268_CR90', 'doi-asserted-by': 'publisher', 'first-page': '6478', 'DOI': '10.1038/s41467-022-33864-y', 'volume': '13', 'author': 'DJ Sullivan', 'year': '2022', 'unstructured': 'Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D (2022) ' 'Analysis of anti-Omicron neutralizing antibody titers in different ' 'convalescent plasma sources. Nat Comm 13(1):6478. ' 'https://doi.org/10.1038/s41467-022-33864-y', 'journal-title': 'Nat Comm'}, { 'key': '268_CR91', 'doi-asserted-by': 'publisher', 'unstructured': 'Sullivan DJ, Franchini M, Senefeld JW, Joyner MJ, Casadevall A, Focosi D ' '(2023) Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 ' 'potently neutralizes BQ1.1 and XBB. J General Virol. ' 'https://doi.org/10.1101/2022.11.25.517977', 'DOI': '10.1101/2022.11.25.517977'}, { 'issue': '18', 'key': '268_CR92', 'doi-asserted-by': 'publisher', 'first-page': '2133', 'DOI': '10.1007/s40265-021-01626-7', 'volume': '81', 'author': 'YY Syed', 'year': '2021', 'unstructured': 'Syed YY (2021) Regdanvimab: first approval. Drugs 81(18):2133–2137. ' 'https://doi.org/10.1007/s40265-021-01626-7', 'journal-title': 'Drugs'}, { 'key': '268_CR93', 'doi-asserted-by': 'publisher', 'unstructured': 'Titong A, Gallolu Kankanamalage S, Dong J, Huang B, Spadoni N, Wang B et ' 'al (2022) First-in-class trispecific VHH-Fc based antibody with potent ' 'prophylactic and therapeutic efficacy against SARS-CoV-2 and variants. ' 'Sci Rep 12(1):4163. https://doi.org/10.1038/s41598-022-07952-4', 'DOI': '10.1038/s41598-022-07952-4'}, { 'issue': '7874', 'key': '268_CR94', 'doi-asserted-by': 'publisher', 'first-page': '103', 'DOI': '10.1038/s41586-021-03817-4', 'volume': '597', 'author': 'MA Tortorici', 'year': '2021', 'unstructured': 'Tortorici MA, Czudnochowski N, Starr TN, Marzi R, Walls AC, Zatta F et ' 'al (2021) Broad sarbecovirus neutralization by a human monoclonal ' 'antibody. Nature 597(7874):103–108. ' 'https://doi.org/10.1038/s41586-021-03817-4', 'journal-title': 'Nature'}, { 'key': '268_CR95', 'doi-asserted-by': 'crossref', 'unstructured': 'Touret F, Giraud E, Bourret J, Donati F, Tran-Rajau J, Chiaravalli J et ' 'al (2022) Enhanced neutralization escape to therapeutic monoclonal ' 'antibodies by SARS-CoV-2 Omicron sub-lineages. iScience. ' 'https://doi.org/10.1016/j.isci.2023.106413', 'DOI': '10.1101/2022.12.22.521201'}, { 'key': '268_CR96', 'unstructured': 'Update on AZD7442 STORM CHASER trial in post-exposure prevention of ' 'symptomatic COVID-19 (2022). Accessed online at ' 'https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html ' 'on 21 Feb 2022'}, { 'key': '268_CR97', 'doi-asserted-by': 'publisher', 'unstructured': 'Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, Guo Z et al (2023) ' 'Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 ' 'BA.2.86 variant. Lancet Infect Dis. ' 'https://doi.org/10.1016/S1473-3099(23)00575-3', 'DOI': '10.1016/S1473-3099(23)00575-3'}, { 'key': '268_CR98', 'unstructured': 'US Food and Drug Administration (FDA) (2021) Clinical memorandum Re: EUA ' '26382. Product: COVID-19 Convalescent Plasma. Issued on December 27, ' '2021 at https://www.fda.gov/media/141477/download'}, { 'key': '268_CR99', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2022.105252', 'volume': '198', 'author': 'L Vangeel', 'year': '2022', 'unstructured': 'Vangeel L, De Jonghe S, Maes P, Slechten B, Raymenants J, André E et al ' '(2022) Remdesivir, Molnupiravir and Nirmatrelvir remain active against ' 'SARS-CoV-2 Omicron and other variants of concern. Antiviral Res ' '198:105252. https://doi.org/10.1016/j.antiviral.2022.105252', 'journal-title': 'Antiviral Res'}, { 'issue': '5', 'key': '268_CR100', 'doi-asserted-by': 'publisher', 'first-page': 'e162', 'DOI': '10.1016/j.jinf.2022.07.014', 'volume': '85', 'author': 'C Vellas', 'year': '2022', 'unstructured': 'Vellas C, Kamar N, Izopet J (2022) Resistance mutations in SARS-CoV-2 ' 'Omicron variant after tixagevimab-cilgavimab treatment. J Infect ' '85(5):e162–e163. https://doi.org/10.1016/j.jinf.2022.07.014', 'journal-title': 'J Infect'}, { 'issue': '2', 'key': '268_CR101', 'doi-asserted-by': 'publisher', 'first-page': '279', 'DOI': '10.1016/j.cell.2022.12.018', 'volume': '186', 'author': 'Q Wang', 'year': '2023', 'unstructured': 'Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y et al (2023b) Alarming ' 'antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. ' 'Cell 186(2):279–86.e8. https://doi.org/10.1016/j.cell.2022.12.018', 'journal-title': 'Cell'}, { 'key': '268_CR102', 'doi-asserted-by': 'publisher', 'unstructured': 'Wang X, Jiang S, Jiang S, Li X, Ai J, Lin K et al (2023a) Neutralization ' 'of SARS-CoV-2 BQ.1.1 and XBB.1.5 by breakthrough infection sera from ' 'previous and current waves in China. bioRxiv. ' 'https://doi.org/10.1101/2023.02.07.527406', 'DOI': '10.1101/2023.02.07.527406'}, { 'key': '268_CR103', 'doi-asserted-by': 'publisher', 'unstructured': 'Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R et al. (2023c) Antibody ' 'neutralization of emerging SARS-CoV-2: EG.5.1 and XBC.1.6. bioRxiv. ' 'https://doi.org/10.1101/2023.08.21.553968', 'DOI': '10.1101/2023.08.21.553968'}, { 'key': '268_CR104', 'volume-title': 'Trial in progress: a Phase I/III, randomised, modified double-blind, ' 'placebo- and active-controlled pre-exposure prophylaxis study of the ' 'SARS-CoV-2–neutralising antibody AZD3152 (SUPERNOVA)', 'author': 'C Webber', 'year': '2023', 'unstructured': 'Webber C, Beavon R, Thomas S, Chang LA, Cohen T, Perez J (2023) Trial in ' 'progress: a Phase I/III, randomised, modified double-blind, placebo- and ' 'active-controlled pre-exposure prophylaxis study of the ' 'SARS-CoV-2–neutralising antibody AZD3152 (SUPERNOVA). ECCMID, ' 'Copenhagen'}, { 'issue': '23', 'key': '268_CR105', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2108163', 'volume': '385', 'author': 'DM Weinreich', 'year': '2021', 'unstructured': 'Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R et al ' '(2021) REGEN-COV antibody combination and outcomes in outpatients with ' 'Covid-19. N Engl J Med 385(23):e81. ' 'https://doi.org/10.1056/NEJMoa2108163', 'journal-title': 'N Engl J Med'}, { 'issue': '9', 'key': '268_CR106', 'doi-asserted-by': 'publisher', 'first-page': '3952', 'DOI': '10.1172/jci128437', 'volume': '129', 'author': 'P Weitzenfeld', 'year': '2019', 'unstructured': 'Weitzenfeld P, Bournazos S, Ravetch JV (2019) Antibodies targeting ' 'sialyl Lewis A mediate tumor clearance through distinct effector ' 'pathways. J Clin Investig 129(9):3952–3962. ' 'https://doi.org/10.1172/jci128437', 'journal-title': 'J Clin Investig'}, { 'issue': '3', 'key': '268_CR107', 'doi-asserted-by': 'publisher', 'first-page': '652', 'DOI': '10.1016/j.jmb.2007.02.024', 'volume': '368', 'author': 'H Wu', 'year': '2007', 'unstructured': 'Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK et al (2007) ' 'Development of Motavizumab, an ultra-potent antibody for the prevention ' 'of respiratory syncytial virus infection in the upper and lower ' 'respiratory tract. J Mol Biol 368(3):652–665. ' 'https://doi.org/10.1016/j.jmb.2007.02.024', 'journal-title': 'J Mol Biol'}, { 'issue': '10369', 'key': '268_CR108', 'doi-asserted-by': 'publisher', 'first-page': '2193', 'DOI': '10.1016/s0140-6736(22)01938-9', 'volume': '400', 'author': 'MY Wu', 'year': '2022', 'unstructured': 'Wu MY, Carr EJ, Harvey R, Mears HV, Kjaer S, Townsley H et al (2022a) ' 'WHO’s therapeutics and COVID-19 living guideline on mAbs needs to be ' 'reassessed. Lancet 400(10369):2193–2196. ' 'https://doi.org/10.1016/s0140-6736(22)01938-9', 'journal-title': 'Lancet'}, { 'key': '268_CR109', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2022.865401', 'volume': '13', 'author': 'X Wu', 'year': '2022', 'unstructured': 'Wu X, Wang Y, Cheng L, Ni F, Zhu L, Ma S et al (2022b) Short-term ' 'instantaneous prophylaxis and efficient treatment against SARS-CoV-2 in ' 'hACE2 mice conferred by an intranasal nanobody (Nb22). Front Immunol ' '13:865401. https://doi.org/10.3389/fimmu.2022.865401', 'journal-title': 'Front Immunol'}, { 'key': '268_CR110', 'doi-asserted-by': 'publisher', 'unstructured': 'Yamasoba D, Uriu K, Plianchaisuk A, Kosugi Y, Pan L, Zahradnik J et al ' '(2023) Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 ' 'variant. Lancet Infect Dis 23(6):655–656. ' 'https://doi.org/10.1016/S1473-3099(23)00278-5', 'DOI': '10.1016/S1473-3099(23)00278-5'}, { 'key': '268_CR111', 'doi-asserted-by': 'publisher', 'unstructured': 'Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X et al (2023a) ' 'Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86. ' 'Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(23)00573-X', 'DOI': '10.1016/S1473-3099(23)00573-X'}, { 'key': '268_CR112', 'doi-asserted-by': 'publisher', 'unstructured': 'Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A et al (2023b) Fast ' 'evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. ' 'Lancet Infect Dis. https://doi.org/10.1101/2023.11.13.566860', 'DOI': '10.1101/2023.11.13.566860'}, { 'issue': '2', 'key': '268_CR113', 'doi-asserted-by': 'publisher', 'first-page': '157', 'DOI': '10.1038/nbt.1601', 'volume': '28', 'author': 'J Zalevsky', 'year': '2010', 'unstructured': 'Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ et ' 'al (2010) Enhanced antibody half-life improves in vivo activity. Nat ' 'Biotechnol 28(2):157–159. https://doi.org/10.1038/nbt.1601', 'journal-title': 'Nat Biotechnol'}, { 'issue': '3', 'key': '268_CR114', 'doi-asserted-by': 'publisher', 'first-page': '415', 'DOI': '10.1093/infdis/jiab247', 'volume': '224', 'author': 'S Zhou', 'year': '2021', 'unstructured': 'Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF et al ' '(2021) β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal ' 'mutagenesis but is also mutagenic to mammalian cells. J Infect Dis ' '224(3):415–419. https://doi.org/10.1093/infdis/jiab247', 'journal-title': 'J Infect Dis'}, { 'key': '268_CR115', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhou H, Tada T, Dcosta BM, Landau NR (2022) SARS-CoV-2 Omicron BA.2 ' 'variant evades neutralization by therapeutic monoclonal antibodies. ' 'Viruses. https://doi.org/10.3390/v14061334', 'DOI': '10.3390/v14061334'}, { 'key': '268_CR116', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhou P, Song G, He W-t, Beutler N, Tse LV, Martinez DR et al (2022b) ' 'Broadly neutralizing anti-S2 antibodies protect against all three human ' 'betacoronaviruses that cause severe disease. Immunity. ' 'https://doi.org/10.1016/j.immuni.2023.02.005', 'DOI': '10.1016/j.immuni.2023.02.005'}, { 'key': '268_CR117', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D et al (2022c) A ' 'human antibody reveals a conserved site on beta-coronavirus spike ' 'proteins and confers protection against SARS-CoV-2 infection. Sci Transl ' 'Med. https://doi.org/10.1126/scitranslmed.abi9215', 'DOI': '10.1126/scitranslmed.abi9215'}], 'container-title': 'Current Topics in Microbiology and Immunology', 'original-title': [], 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/82_2024_268', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 8, 10]], 'date-time': '2024-08-10T13:04:29Z', 'timestamp': 1723295069000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/82_2024_268'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024]]}, 'references-count': 117, 'URL': 'http://dx.doi.org/10.1007/82_2024_268', 'relation': {}, 'ISSN': ['0070-217X', '2196-9965'], 'subject': [], 'published': {'date-parts': [[2024]]}, 'assertion': [ { 'value': '11 August 2024', 'order': 1, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ChapterHistory', 'label': 'Chapter History'}}]}